Research Triangle Park, North Carolina Saturday, February 15, 2025, 17:00 Hrs [IST] ...

Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability, and even ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...

Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, ...

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years ...

Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Currently, people with high cholesterol face complicated treatment plans, usually taking a range of medications for the rest ...

Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...